Nurlan Jainakbayev

Nurlan Jainakbayev

Auto-generated profile, based on publicly available information

Nurlan Jainakbayev

Kazakh-Russian Medical University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2024 in Innovative Medicine of Kuban
Verified
Journal Article
Open access
PDF file
BAB. A. Akbalaeva
B. A. Akbalaeva
LSL. V. Shulzhenko
L. V. Shulzhenko
IPI. V. Pershukov
I. V. Pershukov
NUN. Raiimbek Uulu
N. Raiimbek Uulu
TBT. A. Batyraliev
T. A. Batyraliev
MKM. R. Kamaliyeva
M. R. Kamaliyeva
Background: Cancer therapy-related cardiac dysfunction (CTRCD) is a new term that encompasses a wide range of potential manifestations and is etiologically associated with a wide variety of cancer treatments. Detection of early subclinical cardiac dysfunction is of great clinical importance.Objective: To assess subclinical CTRCD in women with HER2-positive locally advanced or metastatic breast cancer undergoing a course of anthracyclines (doxorubicin), docetaxel, and trastuzumab. We prospectively enrolled women aged 18-75 years with an established diagnosis of HER2-positive locally advanced or metastatic breast cancer across 3 centers.Material and methods: We monitored 122 women with HER2-positive locally advanced or metastatic breast cancer undergoing a course of anthracyclines (doxorubicin), docetaxel, and trastuzumab using speckle-tracking echocardiography. Based on the treatment protocol, we formed 3 comparison blocks: block 1 (chemotherapy: doxorubicin+cyclophosphamide); block 2 (chemotherapy+targeted therapy: docetaxel+trastuzumab), and block 3 (targeted therapy: trastuzumab).Results: The rate of subclinical CTRCD detection was high and exceeded 20%-30% in all comparison blocks after the 3rd course of chemotherapy, chemotherapy+targeted therapy, and targeted therapy. The rate of subclinical CTRCD increased significantly from the 1st to the 2nd, from the 2nd to the 3rd, from the 3rd to the 4th therapy courses in each block. Comparisons between the blocks were significant only after the 4th course of chemotherapy and the 4th course of targeted therapy (Yates-corrected chi-square, P=.0394); all the other comparisons between the blocks were not significant in terms of subclinical CTRCD rate.Discussion: Given the growing number of patients with breast cancer, such frequent monitoring of the cardiac function is likely to improve the quality of cancer treatment and might have a positive impact on the overall survival of patients with breast cancer. Conclusions: Criteria for frequency of echocardiographic monitoring of cardiac dysfunction in patients with malignant tumors, especially with HER2-positive breast cancer, should be revised.

10 June 2024 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
IPI. V. Pershukov
I. V. Pershukov
BAB. A. Akbalaeva
B. A. Akbalaeva
LSL. V. Shulzhenko
L. V. Shulzhenko
TBT. A. Batyraliev
T. A. Batyraliev
OGO. V. Gurovich
O. V. Gurovich
NRN. N. Rakhalskaya
N. N. Rakhalskaya
Aim. To assess the incidence and timing of subclinical cardiac dysfunction associated with therapy for HER2-positive locally advanced or metastatic breast cancer, and to analyze the difference in time from significant reduction in left ventricular (LV) global longitudinal strain (GLS) to significant reduction in LV ejection fraction (LVEF) (cardiotoxicity "echo-loop").Material and methods. A total of 187 women 58±11 years without baseline cardiac dysfunction with verified HER2-positive locally advanced or metastatic breast cancer who received sequential adjuvant therapy with doxorubicin+cyclophosphamide, docetaxel+trastuzumab and trastuzumab monotherapy were followed up in 4 centers in four countries within 12 months with regular (every 3 weeks) speckle-tracking echocardiographic monitoring.Results. Subclinical cardiac dysfunction associated with breast cancer therapy (CTRCD) appears in each block of therapy after the first course. Its frequency increases significantly after each subsequent course compared to the previous one. By the end of the 4th course in each block of therapy, subclinical CTRCD is noted from 24,6% (almost every 4th patient in the chemotherapy block) to 32,6-33,7% (almost every 3rd patient in the chemotherapy and targeted therapy blocks). In 24 out of 25 cases of severe subclinical CTRCD (96%) with a fall in LVEF 15% was preceded. The time difference from a decrease in LV GLS to a decrease in LVEF <40% (cardiotoxicity "echo loop”) ranges from 5 to 16 weeks depending on the cancer therapy option.Conclusion. Until recently, the period of identified moderate subclini­cal cardiac dysfunction was not used to prescribe therapy for the pre­vention and treatment of cardiotoxicity. Enhanced speckle-tracking echo­cardiographic monitoring may reduce the incidence of severe sub­clinical and overt clinical cardiac dysfunction. Guidelines for car­diotoxicity monitoring should be reviewed to reduce the incidence of se­vere cardiac complications of cancer therapy.

7 July 2025 in Kardiologiia
Verified
Journal Article
Closed access
NUN. Raiimbek Uulu
N. Raiimbek Uulu
IPI. V. Pershukov
I. V. Pershukov
LSL. V. Shulzhenko
L. V. Shulzhenko
BAB. A. Akbalaeva
B. A. Akbalaeva
TBT. A. Batyraliev
T. A. Batyraliev
MKM. R. Kamaliyeva
M. R. Kamaliyeva
Aim To monitor the dynamics of biomarkers during chemotherapy, targeted chemotherapy and targeted monotherapy in patients with HER2-positive breast cancer (BC); to analyze the emergence timing of these changes; to compare early biochemical and echocardiographic criteria; and to determine the best time for assessing latent subclinical cardiac dysfunction. Material and methods Patients with BC (229 women aged 57±11 years) treated sequentially with anthracyclines, a combination of docetaxel and trastuzumab, and trastuzumab monotherapy were examined during three blocks of BC therapy until the development of clinical cardiotoxicity. Time-related changes in high-sensitivity cardiac troponin I, N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular (LV) global longitudinal strain (GLS) and LV ejection fraction (EF) (up to 12 speckle-tracking echocardiograms/up to 12 laboratory tests) were analyzed. Clinical cardiotoxicity was defined as a symptomatic decrease in LV EF ≥10% from the baseline value of 54% or more. Results Clinically significant cardiotoxicity developed in 6.3-10.9% of cases depending on the treatment option for BC. Early manifestations of cardiotoxicity were detected already at 3 weeks after the start of the first course of chemotherapy. For the BC treatment with anthracyclines and targeted chemotherapy with docetaxel and trastuzumab, the markers of clinical cardiotoxicity were high-sensitivity cardiac troponin I, NT-proBNP and GLS LV. For the trastuzumab monotherapy, only GLS LV had a prognostic value. No statistically significant changes in the concentrations of high-sensitivity troponin I and NT-proBNP were found. Conclusion For timely detection of clinical cardiotoxicity, laboratory tests (high-sensitivity troponin I, NT-proBNP) and echocardiography (GLS LV) are recommended to be performed every 3 weeks before the next course of BC therapy. While doing so, their sensitivity will depend on the treatment option for BC.

31 December 2024 in BULLETIN OF SURGERY IN KAZAKHSTAN
Verified
Journal Article
Closed access
KMKazhybek Moshkal
Kazhybek Moshkal
JNJainakbayev N
Jainakbayev N
MVMadyarov V
Madyarov V
Background. At the current stage of surgical development, the problem of prevention of postoperative ventral hernias after abdominal surgeries remains unsolved. The research aims to identify the most effective approaches to the prevention of postoperative ventral hernias and to improve surgical treatment outcomes. Methods. A systematic analysis of existing publications, scientific articles, and clinical guidelines focused on the prevention and treatment of postoperative ventral hernias after abdominal surgeries will be conducted. Special attention will be paid to studies describing various surgical plastic techniques and the application of biological materials. Results. To systematize existing methods for the prevention and treatment of postoperative ventral hernias by analyzing their effectiveness and safety. To identify the most suitable surgical techniques and materials that reduce the risk of developing postoperative ventral hernias. To highlight the need for further research in the application of biological materials and new technologies in the prevention and treatment of postoperative ventral hernias. Conclusion. New technologies and materials, such as biocompatible meshes and antimicrobial sutures, have the potential to enhance treatment outcomes. However, systematic and standardized prevention and diagnostic methods are essential for equipping surgeons to mitigate postoperative ventral hernias risk. Research on collagen status, its various types in connective tissue, and new diagnostic methods will be crucial for improving patient quality of life and reducing surgical risks.

20 January 2021 in International Professional Journal "Medicine"
Verified
Journal Article
Closed access
AZAbay Zhangabylov
Abay Zhangabylov
BBBakytzhan Bimbetov
Bakytzhan Bimbetov
NJNurlan Jainakbayev
Nurlan Jainakbayev
КZКаramyat Zordinova
Каramyat Zordinova
Phospholipids (PL) – lipids that are not involved in accumulation of fatty deposits play a significant role and serve various functions. Firstly, as a component of cell membranes of all cells in the organism. In clinical practice, for the past decades, phospholipids were primarily used as hepaprotective substances, going by the name of “essential phospholipids (EPL)”. Becoming a popular, demanded, well-promoted remedy for the treatment of liver diseases. However, despite the many years of approbation, the existing and sufficientclinicalexperience, discussions regarding their benefits, effectiveness, safety and reliability are still underway and have brought up diametrically opposed views. From complete rejection of EPL as medicinal means, to full recognition of the advertised properties of EPL drugs based on the given manufacturer’s descriptions. For this reason, to clarify the issuing situation, we have conducted a literature search on the object of investigation. Purpose of the study. Search and critical analysis of modern literature sources on the topic of work using the principles of evidence-based medicine. Material and Methods. A critical online review of the literature sources chosen for the research has been carried out in the Web of Science Thompson Reuters, Springer Link and Pubmed databases, as well as in research works and online articles 10 years deep. Inclusion criteria: research papers with a high index of evidence base. Exclusion criteria: literature sources with no evidence, low quality works. Results and Discussion. The articleoutlines the natural role of proteins, lipids and the function of the cytolemma of intracellularorganoids in the restoration of damaged membranes of hepatocytes - de novo. Substantiating the obvious uselessness of using essential phospholipids in the treatment of liver diseases in general, fatty hepatosis in particular. The inability of penetration into liver cells for phospholipids in their native form and their alignment in thehepacyte membrane is indicated, since they belong to different biological species and have a mutually closed genetic system. In the literature search undertaken by us on this issue, the analytical and critical review of scientific literature have also shown that when ingested, essential phospholipids have low bioavailability, as the phospholipids in the chylomicrons do not directly enter the liver, but first the lymphatic system through which they are transported to the adipose tissue of the organism, where they are accumulated and metabolized. With parenteral administration, EPL spreading through the bloodstream can accumulate in other organs, systems, without reaching the liver tissue. For example, the largest amounts of EPL are usually found in the cell membranes of the nervous tissue and the brain. Conclusion. Essential phospholipids in the form of soy lecithin products cannot replace the endogenous phospholipids of the human body - in principle. Keywords: essentialphospholipids, liver cell membranes, hepaprotectors.

31 December 2025 in BULLETIN OF SURGERY OF KAZAKHSTAN
Verified
Journal Article
Closed access
AKA Karabaeva
A Karabaeva
DTD Tazhdinov
D Tazhdinov
GSG Saduakassova
G Saduakassova
III Ibragimova
I Ibragimova
NYN Yesenbayeva
N Yesenbayeva
NJN Jainakbayev
N Jainakbayev
Background: The study aimed to evaluate myocardial status in patients with chronic kidney disease stages III–V and assess the effect of spironolactone in dialysis patients. Materials and Methods: A total of 46 patients with chronic kidney disease stages III–IV and 83 with stage V on maintenance hemodialysis were examined. Thirty-eight hemodialysis patients received spironolactone 25 mg/day for 6 months. Echocardiography was used to assess left ventricular dimensions, myocardial mass and relative wall thickness. Left ventricular hypertrophy was defined as left ventricular mass index ≥125 g/m² in men and ≥110 g/m² in women; relative wall thickness ≥0.45 was considered increased. Results: In spironolactone-treated patients (Group 1), left atrial diameter decreased from 4.58 ± 0.11 cm to 4.40 ± 0.11 cm; end-diastolic diameter from 4.15 ± 0.13 cm to 3.94 ± 0.17 cm; posterior wall thickness from 1.29 ± 0.03 cm to 1.23 ± 0.04 cm; Left ventricular myocardial mass from 238.46 ± 19.11 g to 206.18 ± 21.45 g; and Left ventricular mass index from 132.2 ± 10.81 g/m² to 113.32 ± 11.75 g/m². In untreated patients (Group 2), parameters showed minimal change: left atrial diameter 4.03 ± 0.11 cm to 3.90 ± 0.09 cm; Left ventricular myocardial mass 293.39 ± 17.13 g to 291.52 ± 15.43 g; Left ventricular mass index 173.57 ± 10.47 g/m² to 176.94 ± 10.06 g/m². Conclusion: In anuric hemodialysis patients, spironolactone 25 mg/day significantly reduced left ventricular posterior wall thickness, myocardial mass and volume, and left atrial size, indicating a cardioprotective effect.